Thermo Fisher Scientific Inc. announced that researchers in Germany’s A&M Labs have validated a method that uses Thermo Scientific high-Field Asymmetric waveform Ion Mobility Spectrometry (FAIMS) technology to remove interferences from a drug analysis. Using this method, the researchers can adhere to the guidelines of the FDA to ensure human safety in drug development. Unforeseen analyte interferences can cause validated LC-MS methods to fail. Another impact of co-eluting interferences is data misinterpretation, which could cause dosing errors in human test subjects.
The FAIMS interface for the Thermo Scientific TSQ Quantum series of mass spectrometers works in combination with the H-ESI and APCI ion probes at atmospheric pressure to increase selectivity during analysis. FAIMS provides additional ion filtering, resulting in LC-MS/MS chromatograms with reduced chemical background and endogenous interferences.
www.thermo.com/faims
This article was published in Drug Discovery & Development magazine: Vol. 11, No. 1, January, 2008, pp. 26.
Filed Under: Drug Discovery
